Permanent Pacing in Persistent Atrial Fibrillation

Persistent atrial fibrillation (AF) is usually managed with rate control, rhythm control, anticoagulation, and treatment of cardiovascular risk factors. When the ventricular rate becomes unusually slow, however, clinicians must determine whether the finding reflects medication effect, intrinsic conduction disease, or a reversible systemic problem. A low pulse alone does not automatically establish a need for a pacemaker.

The clinical question is especially important when atrial activity is chaotic and ineffective. In patients with accepted permanent AF, an atrial lead generally offers little practical benefit because there is no reliable sinus rhythm to track. Pacing decisions therefore focus on ventricular support, symptoms, pauses, atrioventricular block, and the safety of medicines required to control the patient’s arrhythmia.

The phrase “current indications for permanent pacing in the setting of persistent atrial fibrillation with slow ventricular response” covers several distinct situations. The strongest indication is usually symptomatic or dangerous bradycardia caused by disease of the atrioventricular conduction system. Careful assessment remains essential because unnecessary implantation exposes patients to procedural risks, device complications, and lifelong follow-up.

Defining Slow Ventricular Response

Slow ventricular response in AF is commonly recognised by a resting ventricular rate below approximately 50–60 beats per minute, although no single rate threshold applies to every patient. A person with a rate of 48 beats per minute may feel entirely well, while another patient may develop presyncope, exercise intolerance, falls, confusion, or breathlessness at a similar rate. Symptoms, pauses, and conduction findings carry greater weight than the pulse number alone.

The rhythm may be continuously slow or intermittently interrupted by long pauses. A prolonged ventricular pause while awake, particularly when associated with syncope or near-syncope, raises concern for significant conduction disease. By contrast, pauses during sleep or transient slowing during vagal episodes require interpretation in context. Sleep apnoea, high vagal tone, and medicines can produce nocturnal bradycardia without creating an independent indication for permanent pacing.

A slow response may also be a consequence of treatment. Beta blockers, digoxin, amiodarone, diltiazem, and verapamil can all reduce ventricular conduction, with risk increasing when medicines are combined or renal function changes. A pacemaker should not be used simply to conceal an avoidable prescribing problem. The intended rate-control strategy, comorbidities, renal function, and the possibility of rhythm restoration should be reviewed first.

Findings That Support Permanent Pacing

Permanent pacing is generally supported when AF is accompanied by symptomatic bradycardia that cannot be corrected by withdrawing or reducing an offending medicine. Symptoms should have a plausible temporal relationship with the slow rate or pauses. Syncope, recurrent presyncope, marked exercise intolerance, worsening heart failure symptoms, and documented low-output episodes are clinically persuasive findings.

High-grade or complete atrioventricular block is a separate and stronger indication, particularly when it is persistent and not attributable to a reversible cause. In this setting, the ventricular escape rhythm may be slow and unreliable even if the patient reports few symptoms. Advanced conduction disease, recurrent ventricular pauses while awake, or a very slow escape rhythm may justify pacing after specialist assessment.

Pacing may be appropriate when essential rate-control or antiarrhythmic treatment causes clinically important bradycardia and there is no reasonable alternative. This is sometimes described as pacing to permit necessary pharmacological therapy. The decision should document why the medicine is required, what alternatives were considered, and how pacing fits with the broader goals of care.

The case is less clear when the patient has asymptomatic slow AF with no high-grade block. Current practice generally avoids implantation based on an isolated resting rate or an arbitrary pause duration. Ambulatory monitoring, exercise assessment, medication review, and observation may be more appropriate. Frailty, falls risk, occupational requirements, and patient preferences should be incorporated into shared decision-making.

Assessment Before Implantation

A 12-lead ECG confirms the rhythm and may reveal bundle branch disease, an escape rhythm, prior infarction, or evidence of advanced conduction abnormality. Extended ambulatory monitoring can correlate symptoms with pauses and identify periods of faster conduction. Infrequent events may require a longer patch monitor or implantable loop recorder when the diagnosis remains uncertain and the consequences of missing bradycardia are substantial.

The clinical assessment should include blood tests for electrolytes, renal function, thyroid disease, and other suspected metabolic contributors. Myocardial ischaemia, infection, medication toxicity, and hypoxia may need targeted evaluation. Echocardiography helps assess left ventricular function, valve disease, chamber size, and the likelihood that pacing-induced dyssynchrony could worsen heart failure.

Exercise testing can be useful when the main complaint is exertional fatigue. In AF, the expected heart-rate response is already irregular, so the test is interpreted for inadequate chronotropic response, symptoms, blood-pressure behaviour, and evidence of ischaemia rather than a fixed sinus-node criterion. Sleep-related slowing should prompt assessment for obstructive sleep apnoea where clinical features support it.

Australian practice also requires attention to access and continuity. A patient living in regional Queensland, Western Australia, or the Northern Territory may need coordinated referral to an electrophysiology service in Brisbane, Perth, Darwin, Sydney, or Melbourne. Remote monitoring and a clear plan for wound review can reduce travel burdens. Public hospital pathways, private insurance, and Medicare-funded consultations may affect timing, but they do not replace the clinical indication.

Selecting The Pacing Strategy

For a patient in accepted permanent AF who needs ventricular support, a single-chamber ventricular pacemaker with rate-responsive function is often appropriate. A VVI or VVIR system avoids the unnecessary complexity of an atrial lead and provides backup when intrinsic ventricular conduction fails. Programming must account for the patient’s activity level, escape rhythm, symptoms, and the amount of expected ventricular pacing.

A dual-chamber system may be considered when AF is intermittent, sinus rhythm is likely to return, or a rhythm-control strategy remains realistic. The label “persistent” does not always mean that AF will be accepted permanently. Planned cardioversion, catheter ablation, or ongoing rhythm-control treatment can alter the value of atrial sensing and pacing. The treating team should clarify whether the long-term rhythm strategy is rate control with permanent AF or an attempt to restore sinus rhythm.

Conduction-system pacing, including His-bundle or left bundle branch area pacing, may be considered when a high ventricular pacing burden is expected, especially in patients with impaired ventricular function or a risk of pacing-induced cardiomyopathy. Cardiac resynchronisation therapy has a more specific role for selected patients with heart failure, reduced ejection fraction, ventricular dyssynchrony, and a substantial need for ventricular pacing. Device choice should follow established heart-failure and pacing criteria rather than the presence of AF alone.

The Australian device market includes established manufacturers and newer conduction-system technologies, with availability influenced by hospital expertise, Therapeutic Goods Administration requirements, procurement arrangements, and reimbursement under the Medicare Benefits Schedule. Discussion should cover battery longevity, remote monitoring, magnetic and electromagnetic considerations, infection risk, lead complications, and future generator replacement.

Follow-Up And Patient Safety

After implantation, follow-up confirms wound healing, lead performance, battery status, programmed rate, and the proportion of paced beats. A patient with AF may still experience symptoms from rapid conduction, ventricular ectopy, heart failure, anaemia, or medication effects, so a pacemaker does not remove the need for broader cardiovascular care. Anticoagulation decisions remain based on thromboembolic risk and bleeding considerations rather than pacing status.

Remote monitoring is increasingly valuable across Australia, particularly for patients who live far from major centres or who face long journeys from towns outside Adelaide, Perth, or Sydney. It can identify lead malfunction, battery alerts, and some clinically important rhythm events between in-person appointments. Patients should understand how alerts are handled and whom to contact for wound problems, syncope, new breathlessness, or device alarms.

Driving advice needs individual documentation. Australian medical fitness-to-drive standards are implemented through state and territory licensing systems, with Austroads guidance informing decisions for private and commercial drivers. A patient who has had syncope or a pacemaker implant may require a temporary restriction, specialist review, or notification under local rules. The advice should be recorded clearly and revisited when symptoms or device programming change.

The broader rhythm plan may include cardioversion, antiarrhythmic therapy, or catheter ablation. Pacing is sometimes used to permit treatment of bradycardia, but it does not treat the atrial fibrillation itself. For readers following developments in electrophysiology, this clinical ablation review provides context for newer pulsed-field ablation technology and its early safety considerations.

Clinical decisions should be individualised by a cardiologist or electrophysiologist, with explicit documentation of symptoms, rhythm evidence, reversible causes, expected pacing burden, and the patient’s goals. Clinicians, researchers, and trainees can engage with the Journal of Arrhythmia community through the journal’s contact information for publication, educational, and professional enquiries.